发现了一种针对TRKA和RET衍生的coproteins的蛋白质溶解向金氏体
Marialuisa Moccia1, Lingzhi Zhang2, Zhengyu Wang3
1Istituto degli Endotipi in Oncologia, Metabolismo e Immunologia "G. Salvatore" (IEOMI) del CNR, Naples, Italia.
Scientific reports
|November 25, 2025
概括
新的蛋白质溶解向化马体 (PROTACs) 有效降解瘤性TRKA和RET蛋白,在细胞系和小鼠模型中显示出强大的抗癌作用. 这凸显了PROTACs作为对抗RET和TRKA驱动癌症的有希望的战略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 热聚氨酸受体激酶A (TRKA) 和在转移过程中重新排列 (RET) 是驱动各种癌症的关键瘤原蛋白.
- 针对这些瘤蛋白对于开发有效的癌症疗法至关重要.
研究的目的:
- 设计和评估针对TRKA和RET的向降解的蛋白质溶解向金马 (PROTACs).
- 评估新型PROTAC化合物的抗增殖疗效和降解机制.
主要方法:
- 开发了22种使用RET/TRKA抑制剂和Cereblon (CRBN) E3结合酶结合体的PROTAC.
- 在乳头甲状腺癌 (TPC-1) 和结直肠癌 (KM12) 细胞系中测试了PROTACs.
- 使用蛋白酶和库林抑制剂研究了降解途径,并在小鼠异种移植中分析了体内疗效.
主要成果:
- 确定了几种能够降解RET和TPM3-TRKA基蛋白的PROTAC.
- 化合物9在各种癌症细胞系中表现出强大的抗增殖活性 (低nM IC50).
- 证实降解是依赖于CRBN的,涉及多基化和蛋白质体通路,有"效应"的证据.
- 化合物20在老鼠异种移植模型中诱导了体内TRKA降解.
结论:
- 通过PROTAC介导的降解是针对RET和TRKA瘤信号的可行和有效策略.
- 新型PROTACs对由RET和TRKA改变驱动的癌症具有显著的治疗潜力.
更多相关视频
相关概念视频
Enzyme-linked Receptors
85.7K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
85.7K
Receptor Tyrosine Kinases
17.8K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
17.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
Conservative Site-specific Recombination and Phase Variation
6.6K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
6.6K


